These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28770824)

  • 1. Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.
    Wang F; Miao MX; Sun BB; Wang ZJ; Tang XG; Chen Y; Zhao KJ; Liu XD; Liu L
    Acta Pharmacol Sin; 2017 Nov; 38(11):1554-1565. PubMed ID: 28770824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin is an effective modifier of multiple UDP-glucuronosyltransferase enzymes: evaluation of its potential to alter the pharmacokinetics of zidovudine.
    Sun H; Zhang T; Wu Z; Wu B
    J Pharm Sci; 2015 Jan; 104(1):244-56. PubMed ID: 25393417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and oral bioavailability in rats of an antiviral and antitumor amino acid phosphoramidate prodrug of AZT-monophosphate.
    Song H; Johns R; Griesgraber GW; Wagner CR; Zimmerman CL
    Pharm Res; 2003 Mar; 20(3):448-51. PubMed ID: 12669967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of ABCG2/BCRP restricts the distribution of zidovudine to the fetal brain in rats.
    Filia MF; Marchini T; Minoia JM; Roma MI; De Fino FT; Rubio MC; Copello GJ; Evelson PA; Peroni RN
    Toxicol Appl Pharmacol; 2017 Sep; 330():74-83. PubMed ID: 28705594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.
    Bélanger AS; Caron P; Harvey M; Zimmerman PA; Mehlotra RK; Guillemette C
    Drug Metab Dispos; 2009 Sep; 37(9):1793-6. PubMed ID: 19487252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute liver failure impairs function and expression of breast cancer-resistant protein (BCRP) at rat blood-brain barrier partly via ammonia-ROS-ERK1/2 activation.
    Li Y; Zhang J; Xu P; Sun B; Zhong Z; Liu C; Ling Z; Chen Y; Shu N; Zhao K; Liu L; Liu X
    J Neurochem; 2016 Jul; 138(2):282-94. PubMed ID: 27168176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats.
    Mays DC; Dixon KF; Balboa A; Pawluk LJ; Bauer MR; Nawoot S; Gerber N
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1261-70. PubMed ID: 1762074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease.
    Kimmel PL; Lew SQ; Umana WO; Li PP; Gordon AM; Straw J
    Blood Purif; 1995; 13(6):340-6. PubMed ID: 8821198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein limits the absorption of the anti-HIV drug zidovudine through rat intestinal segments.
    Quevedo MA; Nieto LE; Briñón MC
    Eur J Pharm Sci; 2011 Jun; 43(3):151-9. PubMed ID: 21540109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein and multidrug resistance-associated protein 2 are oppositely altered in brain of rats with thioacetamide-induced acute liver failure.
    Jin S; Wang XT; Liu L; Yao D; Liu C; Zhang M; Guo HF; Liu XD
    Liver Int; 2013 Feb; 33(2):274-82. PubMed ID: 22925079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7).
    Barbier O; Turgeon D; Girard C; Green MD; Tephly TR; Hum DW; Bélanger A
    Drug Metab Dispos; 2000 May; 28(5):497-502. PubMed ID: 10772627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile duct ligation enhances AZT CNS toxicity partly by impairing the expression and function of BCRP in rat brain.
    Qin YY; Xu P; Wu T; Qian CQ; Fan YL; Gen DH; Zhu L; Kong WM; Yang HY; Xu F; Yang YT; Liu L; Liu XD
    Acta Pharmacol Sin; 2020 Feb; 41(2):181-191. PubMed ID: 31142800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal absorption and first-pass elimination of 2', 3'-dideoxynucleosides following oral administration in rats.
    Hasegawa T; Juni K; Saneyoshi M; Kawaguchi T
    Biol Pharm Bull; 1996 Apr; 19(4):599-603. PubMed ID: 8860966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Existence of a flip-flop kinetic model for zidovudine (AZT) after oral administration.
    Melvin GC; Ellison SR; Monk CM; Bates TR
    Res Commun Chem Pathol Pharmacol; 1990 Nov; 70(2):193-204. PubMed ID: 2277865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective modulation of placental and fetal MDR transporters by chronic in utero exposure to NRTIs in Sprague-Dawley rats: Importance for fetoprotection.
    Minoia JM; Filia MF; Roma MI; De Fino FT; Copello GJ; Peroni RN
    Toxicol Appl Pharmacol; 2022 Sep; 450():116170. PubMed ID: 35843342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.
    Court MH; Krishnaswamy S; Hao Q; Duan SX; Patten CJ; Von Moltke LL; Greenblatt DJ
    Drug Metab Dispos; 2003 Sep; 31(9):1125-33. PubMed ID: 12920168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.
    Rong Z; Xu Y; Zhang C; Xiang D; Li X; Liu D
    Life Sci; 2013 Feb; 92(3):245-51. PubMed ID: 23333829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of zidovudine in cats.
    Zhang W; Mauldin JK; Schmiedt CW; Brockus CW; Boudinot FD; McCrackin Stevenson MA
    Am J Vet Res; 2004 Jun; 65(6):835-40. PubMed ID: 15198225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus.
    Liu H; Liu L; Li J; Mei D; Duan R; Hu N; Guo H; Zhong Z; Liu X
    Drug Metab Dispos; 2012 Jun; 40(6):1104-12. PubMed ID: 22393122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
    Wang Z; Yang H; Xu J; Zhao K; Chen Y; Liang L; Li P; Chen N; Geng D; Zhang X; Liu X; Liu L
    Drug Metab Dispos; 2019 Oct; 47(10):1066-1079. PubMed ID: 31399507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.